Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) finished Wednesday with an addition of $0.56 to close at $21.25, an upside of 2.71 percent. An average of 2,925,060 shares of common stock have been traded in the last five days. There was a gain of $2.40 in the past week. The last 20 days have seen an average of 3,884,815 shares traded, while the 50-day average volume stands at 4,194,930.
AUPH stock has decreased by -1.16% in the last month. The company shares reached their 1-month lowest point of $17.65 on 10/06/21. With the stock rallying to its 52-week high on 09/21/21, shares of the company touched a low of $9.72 and a high of $24.18 in 52 weeks. In spite of this, the price is down -12.12% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
23 days have passed since Aurinia Pharmaceuticals Inc. (AUPH) last reported insider trading activity. Huizinga Robert Bindert, who is EVP of Research, most recently acquired $32,500 shares at $23.99 per share on Sep 21. In this transaction, the insider spent $779,533. Chief Business Officer, Martin Michael Robert, disposed of 87,500 shares at a price of $24.02 on Sep 21. The insider now owns more than $2,101,750 worth of shares. Prior to that, Chief Business Officer Martin Michael Robert went on to Sale 28,500 shares at $21.65 each on Sep 20. An amount of $616,975 was transacted.
Aurinia Pharmaceuticals Inc. (AUPH) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 0.34. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 48.53, the price-to-book (PB) ratio at 8.20.
The quick ratio of Aurinia Pharmaceuticals Inc. for the three months ended June 29 was 11.30, and the current ratio was 11.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 98.90% against a 5-year average of -8336.7%. Aurinia Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -191.77%. Its gross profit as reported stood at $147.6 million compared to revenue of $50.12 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. Aurinia Pharmaceuticals Inc.’s return on assets was -40.8% over the last five years. In the past year, the return on investment has been -25.60%, and the 5-year average is -53.4%. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Aurinia Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.36 per share, but it turned out to be -$0.37, a -2.80% surprise. For the quarter, EBITDA amounted to -$47.4 million. Shareholders own equity worth $128.4 million.
From a technical analysis perspective, let’s take a brief look at Aurinia Pharmaceuticals Inc. (AUPH) price momentum. RSI 9-day as of the close on 13 October was 53.77%, suggesting the stock is Neutral, with historical volatility in this time frame at 80.85%.
As of today, AUPH’s price is $20.32 +12.73% or $2.40 from its 5-day moving average. AUPH is currently trading +2.21% higher than its 20-day SMA and +62.96% higher than its 100-day SMA. However, the stock’s current price level is +59.77% above the SMA50 and +55.56% above the SMA200.
The stochastic %K and %D were 49.71% and 41.24%, respectively, and the average true range (ATR) was 1.61. With the 14-day stochastic at 56.69% and the average true range at 1.57, the RSI (14) stands at 54.81%. The stock has reached 0.29 on the 9-day MACD Oscillator while the 14-day reading was at -0.53.
H.C. Wainwright reiterated its a Buy rating on Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), but raised their price target to $30, indicating a potential price increase of 41.18% for the stock.The consensus rating for Aurinia Pharmaceuticals Inc. (AUPH) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AUPH, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is AUPH’s price target for the next 12 months?
Analysts predict a range of price targets between $23.00 and $35.00, with a median target of $31.00. Taking a look at these predictions, the average price target given by analysts for Aurinia Pharmaceuticals Inc. (AUPH) stock is $30.00.